Search Results
Your search for ,now matches 6673 pages
Showing 401 - 450Duration of Postmastectomy Radiation Therapy in Patients Planning Breast Reconstruction
An accelerated course of postmastectomy radiation therapy may not increase complications in patients with breast cancer undergoing breast reconstruction, according to recent findings presented by Poppe et al at the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract 1) and ...
Navigating Uncharted Waters in the Post-Chevron Sea Change
It is not often that the oncology community looks to the Supreme Court to forecast its future. In 2024, two decisions seemingly unrelated to health care were issued that are likely to have a monumental impact on oncology care delivery. The Court’s rulings—on June 28, Loper Bright Enterprises et ...
HIMALAYA: 5-Year Analysis Confirms Survival Benefit of STRIDE Regimen in Hepatocellular Carcinoma
An updated overall survival analysis of the phase III HIMALAYA study, now at 5 years, confirms the benefit for the STRIDE regimen of the monoclonal antibodies durvalumab plus tremelimumab in unresectable hepatocellular carcinoma.1 [The STRIDE regimen consists of a single priming dose of...
Standard Chemoradiation May Be Superior to Deintensification Approaches in Patients With HPV-Associated Oropharyngeal Cancer
Deintensified treatment involving a lower radiation dose and immunotherapy in place of chemotherapy may not perform as well as a more rigorous chemoradiation treatment approach in patients with early-stage human papillomavirus (HPV)-associated oropharyngeal cancer, according to new findings...
Intensity-Modulated Radiation Therapy and Proton-Beam Therapy May Offer Equally High Quality of Life and Tumor Control in Patients With Localized Prostate Cancer
Two types of contemporary radiation therapy—proton-beam therapy or intensity-modulated radiation therapy—may provide comparable rates of tumor control with no differences in patient-reported quality of life among patients with low- and intermediate-risk prostate cancer, according to new findings...
Immunotherapy/Chemoradiotherapy for Patients With Limited-Stage Small Cell Lung Cancer
Findings of a multi-institutional phase III trial indicated that people with limited-stage small cell lung cancer may benefit from the addition of immunotherapy to chemoradiotherapy, but not if both treatments are given simultaneously, new research finds. The results suggest that the timing of when ...
Cisplatin Shortage Led to Treatment Alternatives for Head and Neck Cancer, Significantly Increasing Cost
The alternative use of the monoclonal antibody cetuximab during the shortage of cisplatin in the treatment of head and neck cancer resulted in a 16% total cost increase, leading to a 144-fold increase in costs at the administrative level, impacting payer costs and patient cost-sharing amounts,...
Adjuvant Pembrolizumab Following Surgery May Improve Cancer-Free Survival in Patients With High-Risk Urothelial Carcinoma
Treatment with the immunotherapy agent pembrolizumab may nearly double the length that patients with high-risk, muscle-invasive urothelial carcinoma are cancer free following surgical removal of the bladder, according to a recent study published by Apolo et al in The New England Journal of...
A Clinical Trial Has Halted Progression of Merkel Cell Carcinoma and Allowed Me to Pursue My Love of Music
At the age of 75, I’m just happy to still be here and be able to continue to contribute to my musical community. When I was diagnosed with Merkel cell carcinoma in 2021, I had never heard of the cancer and didn’t realize how aggressive and deadly it is. It was especially surprising to get such a...
Combination Targeted Therapy Produces Durable Remissions in Some Patients With Relapsed Diffuse Large B-Cell Lymphoma
The results from a phase Ib/II study of a five-drug targeted therapy regimen—venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR)—in the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) showed the treatment produced durable remissions and potential...
ASCO Presents Ethan Basch, MD, MSc, FASCO, With the Joseph Simone Quality Care Award
ASCO will recognize Ethan Basch, MD, MSc, FASCO, a medical oncologist and Distinguished Professor at the University of North Carolina, with the Joseph Simone Quality Care Award and Lecture at the 2024 ASCO Quality Care Symposium. This year’s meeting will be held in San Francisco and online on...
Immunotherapy Combination May Improve Long-Term Survival in Patients With Metastatic Melanoma
Researchers have found that about 50% of patients with metastatic melanoma treated with a combination of nivolumab and ipilimumab experienced cancer-free survival of 10 years or longer, according to a recent study published by Wolchok et al in The New England Journal of Medicine. Background In...
Use of Immune Checkpoint Inhibitors Under Study in High-Risk, Hormone Receptor–Positive, Early-Stage Breast Cancer
Clinical trials are now demonstrating the value of immune checkpoint inhibitors as neoadjuvant therapy in certain subsets of patients with hormone receptor–positive, HER2-negative breast cancer. Hope S. Rugo, MD, FASCO, described this newer approach—specifically, which subsets of patients may...
The Formative Years of Medical Oncology in the United States: A Rough and Tumble Road, Part 2
Medical oncology had a turbulent beginning, as we explained in part 1 of this commentary published in the September 25, 2024, issue of The ASCO Post. And although no other specialty we know of struggled as much, with perseverance and time, it had become a stable specialty of internal medicine by...
The Formative Years of Medical Oncology in the United States: A Rough and Tumble Road, Part 1
Medical oncology had a turbulent beginning. No other specialty we know of struggled as much. But by 1980, it had become a stable specialty of internal medicine and was off and running—with the major problem of how to marshal available resources to freely test the myriad opportunities presented by ...
Studies Show Immunotherapy Improves Long-Term Survival in Growing Number of Cancers
The results of numerous large international studies reported at the European Society for Medical Oncology (ESMO) Congress 2024 showed that immunotherapy improves long-term overall survival in patients with a variety of cancer types, including advanced melanoma,1,2 triple-negative breast cancer,3...
5-Year Analysis of Phase III HIMALAYA Confirms Survival Benefit of STRIDE in Hepatocellular Carcinoma
An updated overall survival analysis of the phase III HIMALAYA study, now at 5 years, has confirmed the robust benefit for the STRIDE regimen of durvalumab plus tremelimumab in unresectable hepatocellular carcinoma.1 At the European Society for Medical Oncology (ESMO) Congress 2024 (Abstract...
Two Recent Studies Provide Evidence That Breastfeeding After Breast Cancer May Be Safe
Women who breastfeed after treatment for breast cancer—including those with germline BRCA-mutated disease—may not be at increased risk of cancer recurrence or new breast cancers, according to two recent international studies presented by Blondeaux et al (Abstract 1815O) and Peccatori et al...
Study Supports Universal Genetic Testing of Newly Diagnosed Patients With Invasive Breast Cancer
In a cross-sectional study reported in JAMA Network Open, Rezoug et al found that universal genetic testing identified immediately actionable and established germline pathogenic variants in more than 1 in 20 newly diagnosed patients with invasive breast cancer and was associated with systemic...
Phase III ALEXANDRA/IMpassion030: No Survival Benefit for Adjuvant Atezolizumab in Triple-Negative Breast Cancer
In patients with early-stage triple-negative breast cancer, the addition of atezolizumab to standard adjuvant chemotherapy provided no benefit over chemotherapy alone in the final analysis of the phase III ALEXANDRA/IMpassion030 trial. The results were presented at the 2024 European Breast Cancer...
Use of Immune Checkpoint Inhibitors Under Study in High-Risk, Hormone Receptor–Positive, Early-Stage Breast Cancer
Clinical trials are now demonstrating the value of immune checkpoint inhibitors as neoadjuvant therapy in certain subsets of patients with hormone receptor–positive, HER2-negative breast cancer. Hope S. Rugo, MD, FASCO, described this newer approach—specifically, which subsets of patients may...
Prescription for Progress: Lancet Oncology Commission’s Practical Strategies for Global Cancer Surgery
In certain regions of the world, cancer claims more lives than HIV, tuberculosis, and malaria combined, yet surgery has been relegated to the sidelines of global health initiatives. This critical need to address global inequities in access to safe, timely, and affordable cancer surgery led to the...
T-DXd Effective for Breast Tumors With HER2-Low and HER2-Ultralow Expression in Earlier Line of Therapy
In patients with hormone receptor–positive metastatic breast cancers with HER2-low or HER2-ultralow expression, treatment with the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) was found to be superior to chemotherapy after one or more lines of endocrine therapy. In...
Cancer Has Robbed Me of My Fertility and My Olympic Dreams
I was a track and field athlete throughout college, and my goal was to try out for the Olympics, but cancer had other plans for me. In 2010, while in my senior year in college, I began having sharp, shooting pains in my shoulders, which I initially attributed to overzealous training. But the pain...
Olaparib May Be Effective Without Hormone Therapy in Some Men With Biochemically Recurrent Prostate Cancer
Olaparib may be effective in treating men with biochemically recurrent prostate cancer without accompanying hormone therapy, according to a novel study published by Marshall et al in JAMA Oncology. Background Although most men with localized prostate cancer can be cured with surgery or primary...
Early Interventions May Improve Long-Term Academic Achievement in Pediatric Brain Tumor Survivors
Investigators have found that providing early developmental resources may help reduce the adverse effects of brain tumors and cancer therapy on the academic achievement of young pediatric cancer survivors, according to a recent study published by Somekh et al in the Journal of the National Cancer...
Novel Insights Into Multiple Myeloma Progression
Researchers have offered a comprehensive understanding of the progression of multiple myeloma from a treatable condition to a high-risk disease by providing insights into its genetic diversity and subtypes, according to a recent study published by Skerget et al in Nature Genetics. Background...
Breast-Conserving Surgery With or Without Postoperative Radiotherapy in Early-Stage Breast Cancer: 30-Year Update
As reported in The Lancet Oncology by Williams et al, long-term follow-up of the phase III Scottish Breast Conservation Trial indicated that postoperative radiotherapy was associated with a significantly reduced risk of ipsilateral recurrence vs no radiotherapy in patients undergoing...
SCOTUS Ruling Upends Country’s Regulatory Framework, Threatens to Complicate and Delay Health-Care Delivery
The Association for Clinical Oncology (ASCO) has serious concerns about the impact of the Supreme Court’s rulings in Loper Bright Enterprises v Raimondo and Relentless, Inc. v Department of Commerce on cancer care. These decisions overturned the “Chevron deference” or “Chevron doctrine,” a legal...
Gift of Truth: Reflections on a Father’s Cancer Journey
It was a hot and humid Tuesday in July, and I distinctly remember being grateful for the air conditioning in the pastel-shaded waiting room of the oncology outpatient clinic. My father sat silently beside me. We knew this room well, as we did the doctor we had arrived to see. He had been my...
High-Risk Localized HCC: Efficacy of Neoadjuvant Immunotherapy vs Upfront Surgery
Hepatocellular carcinoma is the most common type of primary liver cancer, accounting for about 80% of all primary liver cancers in the United States, and is currently the sixth most common cancer and the fourth most common cause of cancer-related deaths. Although immunotherapy is now a mainstay for ...
Cancer Mortality Among Adults With Learning Disabilities
Investigators have found that adults with learning disabilities may be more likely to die from cancer compared with those in the general population, according to a recent study published by Ward et al in BMJ Open. Background Many cancers are considered either preventable or treatable. However,...
Dietary Risk Factors for Early-Onset Colorectal Cancer
Researchers have found that diet-derived molecules known as metabolites may be the main drivers of early-onset colorectal cancer risk, especially those associated with red and processed meat, according to a recent study published by Jayakrishnan et al in npj Precision Oncology. Background Despite...
Novel Insights May Transform Diagnosis and Treatment of Pediatric Patients With T-Lineage ALL
Researchers have uncovered that T-lineage acute lymphoblastic leukemia (ALL) may be frequently driven by genetic changes in noncoding portions of the DNA, according to a recent study published by Pölönen et al in Nature. The investigators believe these findings may lead to a paradigm shift in...
Discontinuation of CML Therapy: Which Patients Are Ideal Candidates?
With the introduction of tyrosine kinase inhibitors, chronic myeloid leukemia (CML) has become a chronic disease for most patients. Furthermore, we now know that some patients can successfully stop treatment and remain in remission. “Stopping tyrosine kinase inhibitor therapy is something we get a...
Investigating Fungal Bloodstream Infections in Bone Marrow Transplant Recipients
Researchers may have uncovered the mechanisms behind fungal bloodstream infections in patients who receive bone marrow transplants, according to a recent study published by Zhai et al in Nature Medicine. Background A phenomenon known as heteroresistance occurs when a tiny fraction of bacteria...
Novel AI Tool May Predict Risk of Chronic Pain in Patients With Breast Cancer
A novel artificial intelligence (AI) model may prove to be effective at predicting which patients with breast cancer are likely to develop chronic pain, according to a recent study published by Park et al in the Journal of Nursing Scholarship. The findings may help physicians to better understand...
Glofitamab Combination Therapy Shows Survival Benefit in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
A novel treatment regimen with the bispecific antibody glofitamab has demonstrated improvements in survival outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), according to data presented at the European Hematology Association (EHA) 2024 Congress.1 The phase III ...
Generation X and Millennials Have Higher Risk for Many Cancers Compared to Older Generations
Even though cancer rates continue to fall in older populations, the disease is becoming ever more common among younger age groups. A recent analysis of data from 13 cancer registries in the United States published by Rosenberg et al in JAMA Network Open found that those born between 1965 and 1980...
In Remembrance of My Friend, Lyn Denny, MD, PhD: I Will Never Forget Her
I first met Lyn Denny, MD, PhD, in Ghana, in 2004, when she became the Secretary Treasurer of AORTIC and brought the organization back to life. We’ve been friends ever since. I equate Lyn’s unwavering dedication to bringing health equity to women in Africa to Nelson Mandela’s fight for social...
PIK3CA-Mutated Metastatic Breast Cancer
This is Part 2 of Next-Generation Therapies for Metastatic HR-Positive Breast Cancer: Where Are We Headed?, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Virginia Kaklamani, William Gradishar, and Komal Jhaveri discuss the...
ESR1-Mutated Metastatic Breast Cancer
This is Part 1 of Next-Generation Therapies for Metastatic HR-Positive Breast Cancer: Where Are We Headed?, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Virginia Kaklamani, William Gradishar, and Komal Jhaveri discuss the...
Making a Difference in Global Oncology
“Making a difference in global oncology means framing positive system changes. To me, Dr. Khalid El Bairi is among the global cancer researchers I know who so far has made the largest achievements. “Since the very first interaction with Khalid, what I have captured is passion for the community he...
Updated ASCO Guidance on Cancer-Related Fatigue Expands Patient Options for Interventions
A new update to the ASCO guideline on managing cancer-related fatigue recommends that health care providers urge their patients to exercise, as well as use cognitive-behavioral therapy and mindfulness-based programs to help prevent and treat this prevalent symptom.1 It is estimated that between 30% ...
Failure to Diagnose and Statutes of Limitations: Lavern’s Law and Its Implications for Oncology
When health-care providers, including oncologists, fail to promptly diagnose a medical condition or communicate their diagnosis to their patients, it can have devastating consequences for those patients. In such cases, patients may seek legal recourse through medical malpractice lawsuits, creating...
Multiple Myeloma: Using Absolute Lymphocyte Count to Predict Outcomes After CAR T-Cell Therapy
A simple blood test that measures lymphocyte counts may predict whether patients with relapsed multiple myeloma are going to respond well to chimeric antigen receptor (CAR) T-cell immunotherapy, according to research published by Saldarriaga et al in Blood Advances. The study found that patients...
AACR, ASA, FDA Outline Considerations for Overall Survival Analyses in Clinical Trials
Experts from the American Association for Cancer Research (AACR), American Statistical Association (ASA), and U.S. Food and Drug Administration (FDA) have outlined considerations for clinical trial designs to enhance the collection and analysis of overall survival data in the context of modern-day...
Liquid Biopsy May Enable Monitoring of Disease Evolution in Patients With Metastatic Prostate Cancer
DNA/RNA material contained in circulating extracellular vesicles secreted into the blood stream by tumor cells may capture cancer genomics and transcriptomic evolution in patients with metastatic prostate cancer, according to a recent study published by Casanova et al in Cancer Cell. Background...
Panel Issues First Guidelines to Prevent Anal Cancer in Patients With HIV
Researchers have introduced the first screening and treatment recommendations to prevent anal cancer in patients with the human immunodeficiency virus (HIV), according to new guidelines based on the results of a 2022 study published by Palefsky et al in The New England Journal of Medicine....
Are Eligible Breast Cancer Survivors Receiving Genetic Testing?
Researchers have found that many eligible breast cancer survivors may not be receiving genetic counseling and testing, according to a recent study published by Katz et al in the Journal of Clinical Oncology. Background A growing proportion of cancer treatment and survivorship care relies on...
